Aurora Cannabis has taken a significant step forward in Germany, introducing its first medical cannabis product cultivated on German soil. As Germany continues to relax restrictions in its medical cannabis market, emerging cannabis brands are paving the way for increased access and innovation. The new product is part of Aurora’s IndiMed brand, which focuses on advanced cultivation techniques and a commitment to meeting the needs of German patients.

Consumers can look forward to Island Sweet Skunk, IndiMed’s debut product. This sativa-dominant strain, with a potent 20% THC content and less than 1% CBD, offers a balance of uplifting effects and therapeutic potential.

“We are at the very beginning of a new era,” said Niklas Kouparanis, Co-Founder and CEO of Bloomwell Group. “Cannabis was a widely used remedy hundreds of years ago. After decades of stigmatization, the German government has ushered in a change in our country that also serves as a model of progressive policies for other European countries.”

Image Credit: Aurora Cannabis